QbD Group
    Establishing and Maintaining the Right Level of Clinical Evidence under the EU IVDR

    Establishing and Maintaining the Right Level of Clinical Evidence under the EU IVDR

    This article offers a breakdown of the three key pillars of clinical evidence: scientific validity, analytical performance, and clinical performance. Clear guidance on tailoring your approach based on device risk class and type is provided, along with best practices for evaluating the state of the art and integrating it into your performance evaluation. It clarifies postmarket performance follow-up (PMPF) requirements and how they support your benefit-risk assessment.

    raps_europe_logo
    raps_europe_logo
    We’re proud to highlight a new publication by Pieter Bogaert, PhD—senior RA IVD consultant at QbD Group—recently featured in RAPS Regulatory Focus. In this expert piece, Pieter shares practical insights for IVD manufacturers striving to meet the EU IVDR’s evolving clinical evidence requirements.

    In the EU, demonstrating safety and effectiveness is not a one-time task. Under the IVDR, clinical evidence must be continuously generated and re-evaluated, with a clear link to both state-of-the-art and risk management practices.

    This article offers:

    • A breakdown of the three key pillars of clinical evidence: scientific validity, analytical performance, and clinical performance
    • Clear guidance on tailoring your approach based on device risk class and type
    • Best practices for evaluating the state of the art and integrating it into your performance evaluation
    • Clarification of postmarket performance follow-up (PMPF) requirements—and how they support your benefit-risk assessment

    Whether you're compiling a performance evaluation report or refining your PMS and PMPF strategies, this article is a valuable resource for navigating EU IVDR compliance.

    https://www.raps.org/news-and-articles/news-articles/2025/3/establishing-and-maintaining-the-right-level-of-cl

    RAPS Regulatory Focus_logo
    RAPS Regulatory Focus_logo

    About the author

    Pieter Bogaert-1
    Pieter Bogaert-1

    Pieter Bogaert

    Senior Consultant IVD - Regulatory Affairs

    Pieter Bogaert is a Regulatory Affairs Consultant and ISO 13485 Lead Auditor specializing in in vitro diagnostic medical devices (IVD). With expertise in European regulations, he supports IVD manufacturers, pharma and biotech companies, and EU laboratories in achieving compliance with the In Vitro Diagnostic Regulation (IVDR).

    His consultancy covers regulatory strategy, quality management system compliance, risk management, performance evaluation, and technical documentation submissions. As Co-Chair of the RAPS Belgium Local Networking Group, Pieter actively contributes to the regulatory affairs community. With a background in biomedical sciences, he brings hands-on and managerial experience in medical laboratories, CE-marked IVDs, and in-house developed tests for clinical drug trials.

    Regulatory Affairs
    Regulatory Affairs

    关于作者

    Pieter Bogaert
    Pieter Bogaert

    PhD Biotechnology · Senior Consultant IVD – Regulatory Affairs

    Pieter is a Senior IVD Regulatory Affairs Consultant at QbD Group, specializing in EU IVDR compliance, clinical evidence requirements, and regulatory strategy for diagnostic devices.

    Regulatory Affairs services

    Navigate Regulatory Complexity with Confidence

    Navigate complex regulatory landscapes with expert guidance across pharmaceuticals, medical devices, and IVD.

    Read more
    分享本文

    订阅生命科学领域的最新动态

    专家观点直达您的收件箱——选择您的兴趣。

    绝无垃圾邮件。随时取消订阅。

    Keep reading

    Related articles

    我们使用 Cookie 来改善您的体验

    我们使用必要的 Cookie 来保证网站功能,以及可选的分析 Cookie 来改善我们的服务。 阅读我们的 隐私政策Cookie 政策.